PHARMACOECONOMIC ANALYSIS AT PLANNING THERAPYOF METASTATIC COLORECTAL CANCER: SOME POSSIBILITIES
Based on the data of our own research, which includes 122 patients (n = 122), who were treated in the three medical centers of the KHMAO-Ugra, we have justified the opportunity of using molecular-directed therapy in the treatment of metastatic colon cancer (mRTC) from the point of view of pharmacoeconomic analysis. In the course of the study, we received data about the time to progression (TTP) of the first and second lines of the mRTC therapy, when we performing calculations. The cost-effectiveness indicator for standard regimens (FOLFOX-4, FOLFIRI) and these regimens in combination with bevacizumab and cetuximab have been calculated. In addition, the calculation of the calcemal index for the above regimes has been performed. As a result, the following conclusions are made: the most reasonable from the point of view of pharmacoeconomic analysis in the first line of therapy is the FOLFOX-4 + cetuximabregime, in the second line of therapy FOLFIRI + bevacizumab